Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 000250.KQ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 000250.KQ and 80,000+ other tickers.
See exactly how 000250.KQ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 000250.KQ and 80,000+ other tickers.
Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and produces a wide variety of medications. Its product range features antibiotics, treatments for cardiovascular and respiratory conditions, drugs for the digestive system and ophthalmic use, as well as anti-inflammatory agents. The company was founded on December 29, 1943, and its main operations are based in Hwaseong-si, South Korea.
No recent news available.